Boundless BioBOLD +1.99%14 Current Ratio is 9.87 as of Mar. 2026, which is 28% below its 10-year median of 13.68. GuruFocus rates BOLD with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Boundless Bio ranks better than 77.4% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Boundless Bio's current ratio for the quarter that ended in Mar. 2026 was 9.87.
Boundless Bio has a current ratio of 9.87. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Boundless Bio's Current Ratio or its related term are showing as below:
BOLD'
s Current Ratio Range Over the Past 10 Years
Min: 8.74 Med: 13.68 Max: 22.15
Current: 9.87
During the past 5 years, Boundless Bio's highest Current Ratio was 22.15. The lowest was 8.74. And the median was 13.68.
BOLD's Current Ratio is ranked better than 77.4% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs BOLD: 9.87
Boundless Bio (NAS:BOLD) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Boundless Bio Current Ratio Related Terms
Boundless Bio Current Ratio Historical Data
* Premium members only.
The historical data trend for Boundless Bio's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOLD vs PLRZ, TVRD, TVGN: Current Ratio Comparison
For the Biotechnology subindustry, Boundless Bio's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boundless Bio Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Boundless Bio's Current Ratio distribution charts can be found below:
* The bar in red indicates where Boundless Bio's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boundless Bio (BOLD) has a Current Ratio of 9.87 as of Mar. 2026. This is 28% below median its historical median of 13.68. Over the past decade, Boundless Bio's Current Ratio has ranged from 8.74 to 22.15. According to the industry distribution chart, Boundless Bio ranks #320 out of 1416 companies in the Biotechnology industry, placing it in the top 22.6%.
Is Boundless Bio's Current Ratio too high?
Boundless Bio's current Current Ratio of 9.87 is 28% below median its 10-year median of 13.68. Over the past 10 years, this metric has ranged from a low of 8.74 to a high of 22.15. The Biotechnology industry median Current Ratio is 3.89. Boundless Bio's value of 9.87 is 154.1% above this industry median. Based on the distribution chart, Boundless Bio ranks #320 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Boundless Bio has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Boundless Bio's Current Ratio compare to PLRZ and TVRD?
According to the Biotechnology industry distribution chart, Boundless Bio ranks #320 out of 1416 companies for Current Ratio. This places Boundless Bio in the top 23% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Boundless Bio's value of 9.87 is 154.1% above this benchmark. Historically, Boundless Bio's own Current Ratio has ranged from 8.74 to 22.15 over the past decade. While the company's 10-year median is 13.68 vs. the industry median of 3.89, Boundless Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boundless Bio's current Current Ratio of 9.87 is 154.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boundless Bio's current Current Ratio is 9.87, which is 28% below median its own 10-year median of 13.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boundless Bio stock overvalued right now?
Boundless Bio (BOLD) has a current Current Ratio of 9.87. The current Current Ratio is 9.87, which is 28% below median its 10-year median of 13.68 and 154.1% above the Biotechnology industry median of 3.89. Boundless Bio's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Boundless Bio (BOLD), the current Current Ratio is 9.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
14GF Score
Get the complete analysis for BOLD
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOLD has been successfully added to your 
